Patents

Inovio Biomedical Announces Needle-Free Electroporation Patent

Published in Cancer Weekly, March 6th, 2007

Inovio Biomedical Corp. (AMEX:INO), which is focused on the development of DNA vaccines and a novel tumor ablation therapy, announced that the US Patent and Trademark Office has issued to Genetronics, Inc., Inovio's wholly-owned subsidiary, US Patent number 7,171,264, titled "Intradermal Delivery of Active Agents by Needle-Free Injection and Electroporation."

This patent adds to Inovio's growing patent estate relating to the delivery of genes and drugs to a variety of tissues. It specifically claims a novel method of delivering biological material, including DNA vaccines, to skin using a needle-free method of electroporation. Electroporation uses brief, controlled...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-03-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry